Cataloging interethnic differences in the distribution of genotypes of drug metabolic genes provides valuable information for profiling the pharmacogenetics of a population. We used PCR analysis to catalog the frequencies of alleles and genotypes for CYP1A1, NAT2, GSTs, MTHFR, MTR (MS) and NQO*1 in Arabs. The frequencies of alleles and/or genotypes for CYP1A1*2A, GSTT1 null, GSTT1 and GSTM1 double null, and GSTP1 A1578G in Arabs were significantly higher than those reported in Caucasians. However, the distribution of NAT2 acetylator phenotypes in both populations was similar. In contrast, the frequencies of MTHFR 677T allele and the combined (677 þ 1298) genotypes for low activity were lower than those reported in Caucasians. Other alleles in Arabs, including CYP1A1 T3801C and GSTP1 A1578G were present in frequencies similar to Africans. The overall profile of variations in metabolism genes in Arabs is thus unique.
INTRODUCTION
Variations of an individual's response to cancer therapy can be ascribed to heterogeneity in disease, for example p53 status of the tumor, and/or to heterogeneity in the patient. The latter is often dictated by polymorphisms in genes that encode transporters, 1,2 receptors, 3 DNA repair enzymes, 4 drug targets 5 and genes involved in the metabolism of xenobiotics. 6 Variations in metabolic genes can result in alterations in the efficiency of phase I and phase II detoxification mechanisms as well as in other metabolic pathways of micronutrients, like folate. Specific variations occur in cytochrome P450 (CYPs), 7, 8 glutathione S-transferases (GSTs), 9,10 N-acetyltransferase genes (NAT), 11 NAD(P)H : quinone oxidoreductase genes (NQO*1), 7, 8 methionine synthease (MS/ MTR) and methylenetetrahydrofolate reductase (MTHFR). 12, 13 These same polymorphisms may also modulate genetic susceptibility to cancer.
There is recent evidence that these polymorphisms significantly influence the outcome of multichemotherapeutic regimens, for example those used in acute leukemias. 8, 9 This effect in an individual patient is (unlike the effect on risk of cancer) less prone to be influenced by lifestyle factors and would remain similar in different ethnic populations. However, the frequency of such polymorphisms may vary in different ethnicities [14] [15] [16] and thus the toxicity costs of chemotherapy in the population overall could be different.
Chemotherapy regimens developed in US and Europe eventually become 'standards' of treatment in many world regions. Furthermore, treatment outside the Euro-American setting is often conducted in the absence of substantial follow-up analyses, precluding the assessment of the toxicity costs of such regimens in that population. Thus the identification of similarities or differences in the frequency of polymorphisms that modify clinical outcome would provide valuable information. While some ethnic groups may be included in present day clinical trials in the US, it is unlikely that all groups are well represented. The cataloging of polymorphisms in other geographies should provide an impetus towards rational and regionally tailored clinical trials and refinement of therapies.
Recent comprehensive reports of variations in the frequency of polymorphisms of metabolic genes profiled Caucasians, Asians and Africans but not Arabs.
14-16 Therefore, we conducted this study to provide such information from the Middle Eastern Arabs. The data indicate that the overall profile of polymorphic genes is unique and provide the first framework on the population genetic structure of drug response and cancer susceptibility in the Arab population. Tables 1-3 provide detailed information on the frequency of the multiple alleles and/or genotypes analyzed. Due to PCR failure, a small number of samples could not be analyzed for some polymorphisms and this information is included. It is unlikely that these few losses substantially influenced the overall results. We have also calculated genotype frequencies and these should, given the sample size, provide a guide for estimations of the population genotype frequencies. Except for GSTT1 and GSTM1, where heterozygotes could not be resolved, all other genotypes were in Hardy-Weinberg equilibrium.
RESULTS
Three polymorphisms in the CYP1A1 gene were analyzed in Arabs: T3801C, A2455G and C2453A (Table 1) . Based on these genotypic data, we calculated allelic frequencies as 20.3% for 3801C, 7.6% for 2455G and 19.4% for 2453A. Analysis of the combination of T3801C and A2455G (Table  1) revealed that the frequency of the wild-type allele was almost 80%, *2A allele was 13%, *2B allele was 6.8% and *2C allele was only 0.5%.
For GSTT1 and GSTM1 we determined the frequency of the null genotypes as 25 and 54.6%, respectively. Of interest was the resulting combined frequency of GSTT1 and GSTM1 double nulls (17.2%). Table 2 shows the distribution of GSTP1 variants in Arabs. The derived frequency of the 1578G allele was 39.7% and that of the 2293T allele was 12.6%. Table 2 also lists the data on the polymorphisms for MTHFR C677T, MTHFR A1298C, MTR A2756G and NQO*1 C609T from which variant allele frequencies were 14.9, 31.7, 18.9 and 23.9%, respectively. We have also analyzed the combination of both polymorphisms in MTHFR. The genotype that encodes for a full activity enzyme (wild type, CCAA) represented a high fraction (30.8%) of the population. In contrast, those genotypes that code for an enzyme with low activity (CTAC, CTCC, TTAA, TTAC and TTCC) were less represented (13.6%). The frequency of the Of the major NAT2 alleles, the variant allele 5B had the highest frequency (40.6%), followed by 6A (21.6%), 4 (16.8%), 13 (5.7%) and 5A (3.5%). Other alleles had frequencies less than 3%. Table 3 shows the distribution of the most common genotypes and phenotypes (acetylator status) in Arabs. The 5B/5B genotype was the most common in Arabs (22.2%), followed by 5B/6A (17.7%) and 4/5B (10.1%). Notably, the frequency of wild type (4/4) was only 3.9%.
DISCUSSION
Cancer treatment is evolving on two fronts: (1) development of molecularly targeted agents and (2) utilization of pharmacogenomics and pharmacogenetics. 17 The identification of polymorphisms that confer changes in the ability to metabolize or activate antitumor agents provides the potential to diminish toxicity and individualize therapy. 5 Such polymorphisms may also be relevant to the efficacy of rendering palliative care. 18 In addition to this pharmacogenomic relevance, most of these polymorphic genes are etiologically relevant because they metabolize a range of environmental carcinogens. [19] [20] [21] [22] The eight genes analyzed in this report include GSTM1, GSTT1, GSTP1, MTHFR, MTR (MS), NQO*1, CYP1A1 and NAT2. Variations within these genes have been previously demonstrated to influence drug efficacy and toxicity and also to modify individual susceptibility to cancer. 7, 9, 10, 13, 21, 22 Thus, GSTs participate in the metabolism of alkylating agents, anthracyclines and steroids. [23] [24] [25] Variations in GSTT1 and GSTMI can significantly influence treatment outcome, 9,10 while the catalytic activity of CYP1A1 modulates the response to synthetic glucocorticoids. 26, 27 Similarly, toxicity associated with methotrexate is influenced by the folate-metabolizing enzymes MTHFR and MTR. 13 Variations in NAT2 influence the pharmacokinetics of amonafide, a drug with demonstrated activity in breast cancer and leukemia. 28 The distribution of genotypes of these metabolic genes is available for multiple populations [14] [15] [16] but not for Arabs. In this study, we provide a reference database of allelic frequencies in Arabs. Although this may have limitations due to the nature of the subjects enrolled (preponderance of male blood donors), previous reports have indicated only minimal influence of age and gender on the distribution of these polymorphisms in a given population. Additional information will be required to assess whether regional gradients of allele frequencies exist among the various neighboring countries, as previously described in the European population. 29 As seen in Figure 1 , the population genetic structure of the Arabs is unique and characteristic, resembling more that of Caucasians for some alleles and that of Africans for other alleles. At least at these loci, there is very little similarity in genotype/allele frequencies with Far East Asians.
Statistical analyses showed that the allelic frequency of CYPA1 3801C in Arabs is only comparable to that reported in Africans. The allelic frequency of 2455G, while closer to Caucasians, is significantly different from all other populations. The genotype frequency of CYP1A1*2A in Arabs is similar to Asians, but CYP1A1*2B is significantly lower (Po0.001). As described in other populations, CYP1A1*2C has the lowest frequency and similar to that in Africans. The frequencies of the wild-type allele and wild-type genotype in 
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Arabs were intermediate between those in Caucasians (Po0.001) and Asians/Africans (Po0.001).
GST genes also demonstrate a mixed pattern. While the frequency of GSTT1 null genotype in Arabs is similar to Africans, the frequency of GSTM1 nulls resembles Caucasians and Asians. The proportion of double nulls in Arabs was higher than that reported in Caucasians (Po0.001). Similarly, the frequency of GSTP1 1578G in Arabs is similar to that reported in Africans but GSTP1 2293T allele has the highest proportion (Po0.05).
The frequencies of MTHFR 677T allele and corresponding genotypes in Arabs were similar to those reported in Asians and intermediate between Caucasians and Africans (Po0.001). However, the allelic frequency of MTHFR 1298C is two-fold higher than in Asians (Po0.001) and similar to Caucasians. Analyses of the combined MTHFR C677T and A1298C genotypes in Arab, Caucasian and Asian populations demonstrated that Arabs had the highest proportion of wild-type genotypes (Po0.001) and, thus, the frequency of low activity genotypes was lower The mismatch-primer and NAT2 P100 were used for NAT2 G191A, NAT2 C282T and NAT2 T341C. c NAT2 56 and NAT2 P100 were used for NAT2 C481T and NAT2 G857A. The only significant difference in the distribution of NQO*1 C609T polymorphism was identified between Arabs and Asians (Po0.001).
The distribution of NAT2 genotypes in Arabs was compared to that in Caucasians. While NAT2*5 and *7 are similar, NAT2*6 is lower in our cohort (P ¼ 0.007). The proportion of the corresponding NAT2 acetylator phenotypes was compared to those in other populations. The slow acetylator status in Arabs was similar to Caucasians and significantly higher than in Asians.
Several of these genes (GSTs, CYP1A1 and MTHFR) modulate response to cancer therapy and/or treatmentassociated toxicity. 7, 9, 10, 13, [21] [22] [23] [24] [25] [26] [27] 30 Therefore, the identification of high frequencies of GSTT1 null, GSTP1 variations and carriers of the CYP1A1*2A allele in Arabs has direct clinical relevance. Similarly, the low frequency of the MTHFR 677T allele in Arabs needs consideration. It is likely that multilocus interactions may be important determinants in the individualization of therapy and, in this context, the overall profile of drug response of the Arab population may be relevant to design future clinical trials and should prove valuable in this ethnic group.
On the other hand, the risk of cancer not only depends on the ethnic background but also is modulated by environmental and lifestyle factors. 31, 32 Case-control studies that test the potential risk of these alleles in Arabs will also contribute in the definition of gene-gene and geneenvironment interactions.
Clearly, there are many other metabolic gene polymorphisms associated with response to chemotherapeutic drugs and susceptibility to cancer. For example, genes involved in glucurodination, 28 thiopurine methyltransferase (TPMT), 33 which need to be studied in Arabs.
MATERIALS AND METHODS

Subjects of Investigation
Peripheral blood was obtained from 513 individual healthy blood donors of Middle Eastern Arab origin (95% Saudi Arabians and 5% from other Arab countries such as Jordan, Syria, Lebanon, Yemen) visiting the Blood Bank at KFSHRC, Riyadh, Saudi Arabia. The average age was 37 years and there was a significant preponderance of males (25 : 1). Approval from the Institutional Review Board was obtained to conduct this study.
Genotyping
Genomic DNA was extracted from peripheral blood using the Puregene DNA isolation kit (Gentra, Minneapolis, MN, USA) following the manufacturer's recommendations. The presence or absence of GSTM1 and GSTT1 was determined by multiplex PCR in which b-globin gene was co-amplified as an internal control. PCR-RFLP analyses for MTHFR C677T and A1298C, MTR (MS) A2756G, GSTP1 A1578G and C2295T, NQO*1 C609T, CYP1A1 T3801C, C2455G and C2453A and NAT2 genotypes were performed as previously described with some modifications. 22, [34] [35] [36] [37] We first determined that the use of Hotstart Taq polymerase allowed us to apply the same PCR conditions to optimally amplify each of the variant alleles for all genes studied. PCR reactions were performed in 25 ml containing 50 ng of genomic DNA, 12.5 pmol each primer, 200 mM of each dNTPs, 2.5 mM MgCl 2 and 0.5 U Hotstart Taq DNA Polymerase. After denaturation for 10 min at 951C, each PCR was performed for 35 cycles of 1 min at 951C, 1 min at 591C and 1.5 min at 721C. The final elongation step was 10 min. Negative nontemplate controls were included in each PCR. The sequences of the primers and the corresponding restriction enzymes used in PCR-RFLP analyses are shown in Table 4 . The same aliquot of DNA was used to analyze all SNPs, including fragments as big as 1.2 kb. PCR products were directly analyzed on a 2.5% agarose gel.
Data utilized in this report for allele and genotype frequencies from other ethnic populations were mostly gathered from reviews (HuGE) published between 2000 and 2003. 14, 16, 36, [38] [39] [40] [41] [42] [43] Asians refers to Japanese, Chinese and Korean, African refers to Sub-saharan Africans and AfricanAmericans.
Allele and genotype data obtained by PCR analysis of the candidate genes were entered into an Excel file and all statistical analyses were performed using the SPSS 11.0 statistic software. For comparisons between ethnic groups, the Fisher exact text was used.
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